SEC filing record
Primary Source · SEC.gov

Hemanext Inc.

2025 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2025-08-05Last filing 2025-08-05

Raised

$20M

Investors

29

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Hemanext Inc. is a Delaware corporation that first filed a Form D on December 20, 2016 and most recently amended it on August 5, 2025 in the Other Health Care industry group. The offering claims Rule 506(b) and covers equity. Hemanext Inc. reported $19,978,442 sold from 29 investors of a $24,000,000 total offering as of the Form D filed August 5, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Octavian AG, associated with None as the recipient of sales compensation. Sales commissions are reported as $41,250 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 99 Hayden Avenue, Building B, Suite 620, Lexington, MA 02421.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001305849
Entity NameHemanext Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address99 Hayden Avenue, Building B, Suite 620, Lexington, MA 02421
Phone(781) 301-7463
Former NamesNew Health Sciences, Inc. (until October 25, 2019); New Health Sciences Inc (until April 19, 2006)
Industry / Fund TypeOther Health Care
Securities TypeEquity
First Sale DateJuly 18, 2025
Filing DateAugust 5, 2025
Accession Number0001305849-25-000005
Total Offering Amount$24,000,000
Total Amount Sold$19,978,442
Amount Remaining$4,021,558
Total Investors29
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$41,250 (to Octavian AG)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)MA
Amendment Count12 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

3

latest Aug 5, 2025

Critical / warning

0 / 0

0 watch · 3 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

9

raising, dark, lapsed, closed, pre_sale

Latest event New filer · Aug 5, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 3 filing events with values and deltas, latest 2025-08-05, and alerts on the next one
  • 9 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Andrew Dunham

Executive Officer, Director · Lexington, MA

President, Chief Executive Officer, and Member of the Board of Directors

Eric J. Newman

Executive Officer · Lexington, MA

Vice President, Chief Financial Officer, and Corporate Secretary

Laurel J. Omert

Executive Officer · Lexington, MA

Chief Medical Officer

Laura J. Daniels

Executive Officer · Lexington, MA

Vice President of Product Development

Robert J. Haime

Executive Officer · Lexington, MA

Vice President of Commercial Operations

Jill J. Buckley

Executive Officer · Lexington, MA

Vice President of Human Resources

Stephen A. Eckert

Director · Lexington, MA

Chairman of the Board of Directors

Peter A. Testa

Director · Lexington, MA

William Patrick O'Neill

Director · Lexington, MA

Eduardo Patrick Avayu

Director · Lexington, MA

Paul M. Ness

Director · Lexington, MA

Daan M. Kok

Executive Officer · Lexington, MA

Head of Business Development and Strategy

Ismail M. Kola

Director · Lexington, MA

Geoffrey M. Crouse

Director · Lexington, MA

Philip M. Pead

Director · Lexington, MA

Joseph M. Grogan

Director · Lexington, MA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Octavian AG

Associated broker-dealer: None · Zurich, V8 and outside the United States

Questions About Hemanext Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Hemanext Inc.?

Hemanext Inc. is a Delaware corporation that filed a Form D with the SEC on August 5, 2025 in the Other Health Care industry group. The filing claims Rule 506(b) for an offering of equity.

Is Hemanext Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Hemanext Inc. filed a Form D with the SEC on August 5, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $19,978,442 sold to 29 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Hemanext Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Hemanext Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Hemanext Inc. raised?

Hemanext Inc. reported $19,978,442 sold from 29 investors of a $24,000,000 total offering as of the Form D filed August 5, 2025.

Who can invest in Hemanext Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Hemanext Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Hemanext Inc. and how are they paid?

The Form D names Octavian AG, associated with None as the recipient of sales compensation. Sales commissions are reported as $41,250 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Hemanext Inc.?

The Form D lists 16 related persons: Andrew Dunham, executive officer, director (President, Chief Executive Officer, and Member of the Board of Directors); Eric J. Newman, executive officer (Vice President, Chief Financial Officer, and Corporate Secretary); Laurel J. Omert, executive officer (Chief Medical Officer); Laura J. Daniels, executive officer (Vice President of Product Development); Robert J. Haime, executive officer (Vice President of Commercial Operations); Jill J. Buckley, executive officer (Vice President of Human Resources); Stephen A. Eckert, director (Chairman of the Board of Directors); Peter A. Testa, director, and 8 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Hemanext Inc. located?

The issuer's address on its SEC filings is 99 Hayden Avenue, Building B, Suite 620, Lexington, MA 02421. Its phone number of record is (781) 301-7463. It is organized under the laws of Delaware.

How long is the Hemanext Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 3 amendments are on record for this CIK.

What is Hemanext Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.